Pipeline

iCoat Medical’s product portfolio addresses several health issues that are connected to ischemia reperfusion injury. The table below shows what stage each product candidate has reached in the development cycle.

Trials

Ongoing:

  • ATMIRe – Phase I/IIa (First-in-Human) Double-Blind, Placebo-Controlled, Randomized, Single-Center Trial to Evaluate the Safety and Tolerability of iCM012 for Ex Vivo Kidney Allograft Treatment to Minimize Ischemia-Reperfusion Injury (IRI) and Improve Short- and Long-Term Outcomes after Kidney Transplantation. The patient recruitment was successfully completed in May 2023, and a report with 3-month follow-up data is expected in Q3 2023.

In planning:

  • EMPIRe – Phase IIb/III Trial: An adaptive, double-blind, placebo-controlled, randomized, multicenter study assessing iCM012’s efficacy and safety for ex vivo kidney allograft treatment. Its primary goal is to minimize ischemia-reperfusion injury (IRI) and enhance short- and long-term outcomes post kidney transplantation. Anticipated start: Q1 2024.

For further information, see the press releases.

Pharmaceutical products
Candidate / Project
Usage area
Research
Preclinical studies
Clinical preparation
Phase I/IIa
Pivotal study
Expected next step
iCoat Medical’s technology platform
iCM012
Kidney transplantation
IND approval H1 2024
Other solid organs
Under assessment for next steps
iCM020
iCM012
iCM023
(1st, 2nd, 3rd generation molecules)
Open heart surgery
Pre-clinical studies ongoing
Cell therapies
Ongoing
research
Myocardial infarction
Stroke
Completed
Ongoing
Planning